Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Moderna, inc. save search
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
rna-1010 vaccine influenza phase 3
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Published: 2022-02-22 (Crawled : 13:30) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -2.39%
H: 6.28%
C: 1.9%
respiratory trial vaccine phase 3
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
Published: 2021-12-10 (Crawled : 12:30) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -17.85%
H: 0.0%
C: 0.0%
phase 1 positive vaccine phase 2 phase 3
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
Published: 2021-10-26 (Crawled : 21:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
vaccine phase 3
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
Published: 2021-08-16 (Crawled : 14:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -6.41%
H: 0.08%
C: -1.43%
phase 1 phase 2 phase 3
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 3.82%
H: 1.56%
C: -3.72%
phase 1 phase 2 phase 3
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
Published: 2021-07-07 (Crawled : 13:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.68%
H: 0.04%
C: -4.25%
phase 1 vaccine phase 2 phase 3
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.16%
H: 5.18%
C: 5.04%
covid phase 1 vaccine phase 3 phase 2 covid-19
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
Published: 2021-01-21 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.97%
H: 0.62%
C: -0.63%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.11%
H: 9.36%
C: 6.15%
covid vaccine phase 3 phase 1 phase 2
Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine
Published: 2020-12-31 (Crawled : 17:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.52%
H: 2.71%
C: -5.5%
covid vaccine phase 3 results trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.